These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 32157927)

  • 41. Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome.
    Baillargeon JP; Iuorno MJ; Apridonidze T; Nestler JE
    Metab Syndr Relat Disord; 2010 Apr; 8(2):127-36. PubMed ID: 20156067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen.
    Cittadini E
    Fertil Steril; 2011 Jun; 95(8):e57; author reply e58. PubMed ID: 21514580
    [No Abstract]   [Full Text] [Related]  

  • 43. Endocrine and reproductive effects of polycystic ovarian syndrome.
    Ecklund LC; Usadi RS
    Obstet Gynecol Clin North Am; 2015 Mar; 42(1):55-65. PubMed ID: 25681840
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alpha Lipoic Acid Efficacy in PCOS Treatment: What Is the Truth?
    Guarano A; Capozzi A; Cristodoro M; Di Simone N; Lello S
    Nutrients; 2023 Jul; 15(14):. PubMed ID: 37513627
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinical application of in vitro maturation of human immature oocytes for infertile women with polycystic ovary syndrome].
    Xu YP; Xiang HF; Zou WW; Li ZL; Zhang ZG; Zhou P; Cao YX
    Zhonghua Fu Chan Ke Za Zhi; 2012 Jan; 47(1):14-8. PubMed ID: 22455687
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction.
    Papaleo E; Unfer V; Baillargeon JP; De Santis L; Fusi F; Brigante C; Marelli G; Cino I; Redaelli A; Ferrari A
    Gynecol Endocrinol; 2007 Dec; 23(12):700-3. PubMed ID: 17952759
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Choice of stimulation in polycystic ovarian syndrome: the influence of obesity.
    Galtier-Dereure F; Pujol P; Dewailly D; Bringer J
    Hum Reprod; 1997 Oct; 12 Suppl 1():88-96. PubMed ID: 9403325
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PCOS and infertility.
    Hart R
    Panminerva Med; 2008 Dec; 50(4):305-14. PubMed ID: 19078871
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Consensus on infertility treatment related to polycystic ovary syndrome.
    Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group
    Fertil Steril; 2008 Mar; 89(3):505-22. PubMed ID: 18243179
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Polycystic ovary syndrome in the Indian Subcontinent.
    Allahbadia GN; Merchant R
    Semin Reprod Med; 2008 Jan; 26(1):22-34. PubMed ID: 18181079
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inositols in Polycystic Ovary Syndrome: An Overview on the Advances.
    Facchinetti F; Unfer V; Dewailly D; Kamenov ZA; Diamanti-Kandarakis E; Laganà AS; Nestler JE; Soulage CO;
    Trends Endocrinol Metab; 2020 Jun; 31(6):435-447. PubMed ID: 32396844
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clomiphene citrate is associated with favorable cycle characteristics but impaired outcomes of obese women with polycystic ovarian syndrome undergoing ovarian stimulation for in vitro fertilization.
    Jiang S; Kuang Y
    Medicine (Baltimore); 2017 Aug; 96(32):e7540. PubMed ID: 28796038
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios.
    Nordio M; Basciani S; Camajani E
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5512-5521. PubMed ID: 31298405
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome.
    Heijnen EM; Eijkemans MJ; Hughes EG; Laven JS; Macklon NS; Fauser BC
    Hum Reprod Update; 2006; 12(1):13-21. PubMed ID: 16123051
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
    Nordio M; Proietti E
    Eur Rev Med Pharmacol Sci; 2012 May; 16(5):575-81. PubMed ID: 22774396
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients.
    Monastra G; Unfer V; Harrath AH; Bizzarri M
    Gynecol Endocrinol; 2017 Jan; 33(1):1-9. PubMed ID: 27898267
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Infertility and pregnancy in women with polycystic ovary syndrome.
    Nader S
    Minerva Endocrinol; 2010 Dec; 35(4):211-25. PubMed ID: 21178917
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of metformin supplementation during ovarian stimulation of lean PCOS patients undergoing in vitro fertilization.
    Kumbak B; Kahraman S
    Acta Obstet Gynecol Scand; 2009; 88(5):563-8. PubMed ID: 19306135
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment strategies for the infertile polycystic ovary syndrome patient.
    Tannus S; Burke YZ; Kol S
    Womens Health (Lond); 2015 Nov; 11(6):901-12. PubMed ID: 26626234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.